November 16, 2022

To,
The Manager, Dept. of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001

Dear Sir/Madam,
Subject : Newspaper Publication for Un-Audited Financial Results for quarter and half-year ended September 30, 2022
Reference : Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015
Scrip : 511509

With reference to the above cited subject, we are herewith enclosing the copies of advertisement issued in newspapers on November 16, 2022, in "Financial Express" in English Language and in "Nava Telangana" in Telugu Language, with respect to the UnAudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2022.

This is for your information and records.
Thanking you,
Yours faithfully,
For Vivo Bio Tech Limited


Encl: As above


## e-TENDER NOTICE



## FINKURVE FINANCIAL SERVICES LIMITED

Tell

| Paritulars | QUARTERENDED |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 30.09.202 <br> Unaudited | 30.06.2022 Unaudited |  | 30.09.2022 Unauditer | $\begin{aligned} & 30.09 .2021 \\ & \text { Unaudited } \end{aligned}$ | 31.03.2022 |
| Total Income (Net) | 1090.89 | 830.47 | 622.20 | 1921.35 | 1084.89 | 65.0 |
| Profit / (Loss) from Ordinary Activities after tax (9-10) | 480.45 | 289.24 | 164.22 | 769.69 | 342.29 | 2160.88 |
| Net Profit / (Loss) for the period after tax |  |  |  |  |  |  |
| (after Extraordinary items) | 480.45 | 289.24 | 164.22 | 769.69 | 42.2 | 2160.88 |
| Paid-up Equity Share Capital |  |  |  |  |  |  |
| (face value Rs 1/- each ) | 1,268.58 | 1,268.58 | 1268.58 | 1,268.58 | 1268.58 | 1268.58 |
| Reserves (excluding revaluation reserve as shown |  |  |  |  |  | 14536 |
| in the Balance Sheet of previous year) |  |  |  |  |  |  |
| Earning per share (of Rs. 1/-each) |  |  |  |  |  |  |
| a) Basic and Diluted EPS |  |  |  |  |  |  |
| (before Extraordinary items) (in Rs.) | 0.38 | 0.23 | 0.13 | 0.61 | 0.27 | 1.70 |
| b) Basic and Diluted EPS |  |  |  |  |  |  |
| (after Extraordinary items) (in Rs.) | 0.38 | 0.23 | 0.13 | 0.61 | 0.27 | 1.70 |

## $\underline{\square}$

## एण्ड्र यूल एण्ड कम्पनी लिमिटेड

ANDREW YULE \& COMPANY LIMITED


| Extract of the Unaudited |
| :--- |
| sL |


| $\begin{array}{\|l\|l\|} \hline \mathrm{sin} \\ \mathrm{NO} . \end{array}$ | Pariticulars | Standalone |  |  | Consolidated |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\underset{\substack{3 \text { Months Ended } \\ 30.092022}}{ }$ | $\left.\right\|_{\substack{\text { M. } \\ 30.09 .2022}} ^{6 \text { Month Endod }}$ | Corrosponding 3 months ended 30.09 .2021 | 3 Months Endidd <br> 30.09.2022 | $\underset{\substack{6 M \text { Month } \\ \text { 30.09.2022 } \\ \text { Endod }}}{ }$ | $\underset{\substack{\text { Corrosponding } \\ 3 \text { monthens and } \\ 30.09 .2021}}{ }$ |
|  |  | (Unaudites) | (Unaudtiod) | (Unauditad) | (Unauditiod) | (Unauditiod) | (Unauditae) |
| 1. | Total income from operations (net) | 12635.64 | 188669.03 | 146535.81 | 12635.64 | 18566.03 | 145335.89 |
| 2. | Net Profit / (Loss) for the perlod fbelore Tax, exceptional andior extraordinary items) | 2900.84 | 1100.96 | ${ }^{2955.98}$ | 244.52 | 1530.85 | 184279 |
| 3. | Exceplomal liems | - | - | - | - | - | - |
| 4. | Net Profit (Loss) tor the period before tax (after exceptional andior extraordinary items) | 2900.84 | ${ }^{1100.96}$ | ${ }^{2953.98}$ | ${ }^{2474.52}$ | 1530.85 | 184279 |
| 5. | Net Protié (Loss) tor the period atier thax (after excepitional andor oftraordinary liems) | ${ }^{2521.45}$ | ${ }^{72,1.57}$ | ${ }^{2855.38}$ | ${ }^{2095.24}$ | ${ }^{1151.57}$ | ${ }^{184279}$ |
| 6. | Total Comprehensive Income for the period \|Comprising Profit ] (Loss) for the period (after tax) and Other Comprethensive Income [ather $\operatorname{tax}$ ] | 2521.45 | 72.157 | 2996.04 | 2095.24 | 1151.57 | ${ }^{1944.85}$ |
| 7. | Paid-pp Equily Share Capital (ficece vilue Rs. 2-pere Equiky Share) | 9779.02 | 9779.02 | 9779.02 | 9779.02 | 9779.02 | 979.02 |
| 8. | Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year | - | ${ }^{9256.73}$ | - | - | 28373.16 | - |
| 9. |  | $\begin{aligned} & 0.52 \\ & 0.52 \\ & 0.52 \end{aligned}$ | $\begin{aligned} & 0.15 \\ & 0.15 \end{aligned}$ | $\begin{aligned} & 0.58 \\ & 0.58 \\ & 0 . \end{aligned}$ | $\begin{aligned} & 0.43 \\ & 0.43 \end{aligned}$ | $\begin{aligned} & 0.24 \\ & 0.24 \end{aligned}$ | $\begin{aligned} & 0.38 \\ & 0.38 \\ & 0 . \end{aligned}$ |






IMPORTANT
copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

| VIVO BIO TECH LIMITED |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| CIN: L65993TG1987PLC007163 <br> Registered olfice: 03 Floor, llyas Mohammed Khan Estate, \#8-2-672/5 \& 6, Road No.1, Banjara Hills. Hyderabad, Telangana - 500034 Email: investors@vivobio.com; Website: wwwvivobio.com |  |  |  |  |  |
| extract of un-audited consolidated financial results of vivo bio tech limited FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2022 |  |  |  |  |  |
| Particulars | Quarter Ended |  | Hall-Year Ended |  | Year Ended |
|  | 30.09.2022 | 30.09.2021 | 30.09.2022 | 30.09.2021 | 31.03.2022 |
|  | Un-Audited | Un-Audited | Un-Audited | Un-Auditited | Audited |
| Total Income trom Operations | 1,267.85 | 1,019.84 | 2,394.27 | 2.341 .63 | 5.148.93 |
| 2. Net Profit/ /Loss) for the period (before Tax, Exceptional and/or Extraordinary items\# | 51.13 | 106.60 | 119.77 | 325.66 | 447.2 |
| 3. Net Profit// (Loss) for the period before tax (atter Exceptional and/or Extraordinary items\#) | 51.13 | 106.60 | 119.77 | 325.66 | 447.2 |
| 4. Net Profit/ (Loss) for the period after tax (after Exceptional and/or Extraordinary | 12.05 | 27.71 | 43.66 | 151.65 | 220.16 |
| 5. Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period | 12.05 | 27.71 | 43.66 | 151.65 | 220.16 |
| 6. Equity Share Capital | 1,475.86 | 1,420.45 | 1,475.86 | 1,420.45 | 1,426.35 |
| 7. Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) |  |  |  |  |  |
| i. Basic | 0.08 | 0.20 | 0.30 | 1.07 | 1.56 |
| ii. Diluted | 0.08 | 0.19 | 0.30 | 1.02 | 1.56 |
| Notes: <br> 1. The above Un-Audited Financial Results for the Ouarter and Half year ended September 30,2022 , were reviewed by the Audit Committee and approved by the <br> Board of Directors at their meetings held on November 14, 2022 . These results have been subjected to limited review carried out by the Statutory Auditors. <br> 2. The Consolidated Results include results of all subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life <br> Consultancy Private Limited and Vivobio Consulting Services Private Limited (Formerly Donakantic Consulting Services Private Limited). <br> 3. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required. <br> 4. The above is an Extract of the detailed format of quarterly Un-Audited Financial Results filed with stock exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results is available on the stock exchange website www bseindia. com and Company's website www wivobio. com. <br> 5. Standalone Financial Information of the Company is as under: |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| Particulars |  |  |  |  | Year Ended |
|  |  |  |  |  | $\frac{1.03 .2022}{\text { Audited }}$ |
| Total Income | 1,254.43 | 1,019,84 | 2,380.85 | $2,341.01$ | 5,148.31 |
| Profit before Tax | 50.98 | 106.60 | 119.62 | 325.04 | 447.39 |
| Profit tor the Period | 11.92 | 27.71 | 43.53 | 151.03 | 220.33 |
| Date: 14.11.2022 Place: Hyderabad |  |  |  | For Vivo Bio <br> Kalyan Ra DIN: 0 | Tech Limited <br> Mangipudi <br> 12580 |




నేడు కల్యాణలక్ష్యీ, షాదీముబారక్ చెక్కుల పంపిణీ

## సొంత గూటి కోసం ఎదురుచూపు

|  <br>  <br>  <br>  <br>  <br>  |
| :---: |
| పసుపు, కుంకుమతో శివలింగం |
|  |
|  |
|  |
|  |

## 

మధ్యాహ్న భోజనంలో నాణ్యత తగ్గొద్దు





 No e ఆయిల్ఫామ్ సాగుపై అవగాహన


- పట్టించుకోని పాలకులు, అధికారులు


కెనాల్ భూములు కోల్పోతున్న రైతులకు తగిన పరిహారం అందించాలి

ఒకే రోజు 8 మెడికల్ కాలేజీలను ప్రారంభించడం చరిత్రాత్మకం - స్ఎం కేసึఆర్ ముందుచూపుతో ఆరోగ్య తెలంగాణ




$\qquad$

## కార్మ్కుల హ்ఆర్సీని అమలు చేయాలి

- ప్రతి నెల సబ్చులు, నూనెలు ఇవ్వాలి
- సీఐటీయూ జలల్లా అధ్యక్షుడు సంద

బోయున ఎల్లయ్య




